Read our CEO Richard Marsden's 2023 Letter
5th January 2023
The Need - and Opportunity - to Develop Broad-Spectrum Antivirals by Dr Phillip Monk
3rd January 2023
ITN Lungs Matter
28th November 2022
Synairgen to play key role in respiratory viral infection study
5th September 2022
WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
28th December 2021
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
28th December 2021
Synairgen presents data on antiviral activity of lead asset
8th December 2021
Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
20th October 2021
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
24th May 2021